Scarica l'app Stockscreener
749.44
0.22%
-1.69
Dopo l'orario di chiusura:
765.40
15.96
+2.13%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché REGN Giù?
Forum
Previsione
Precedente Chiudi:
$751.13
Aprire:
$755.73
Volume 24 ore:
921.46K
Relative Volume:
0.94
Capitalizzazione di mercato:
$78.77B
Reddito:
$14.25B
Utile/perdita netta:
$4.58B
Rapporto P/E:
17.94
EPS:
41.7701
Flusso di cassa netto:
$3.88B
1 W Prestazione:
-0.80%
1M Prestazione:
-3.98%
6M Prestazione:
+34.27%
1 anno Prestazione:
+9.05%
Intervallo 1D:
$742.80
$755.73
Intervallo di 1 settimana:
$742.80
$776.25
Portata 52W:
$476.49
$821.11
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Nome
Regeneron Pharmaceuticals Inc
Settore
Industria
Telefono
(914) 847-7000
Indirizzo
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Confronta REGN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
749.44 | 78.94B | 14.25B | 4.58B | 3.88B | 41.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
475.68 | 121.25B | 11.74B | 3.68B | 3.34B | 14.19 |
|
ARGX
Argen X Se Adr
|
847.72 | 52.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
346.79 | 46.18B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
350.00 | 38.73B | 4.98B | 69.59M | 525.67M | 0.5197 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-07 | Aggiornamento | BofA Securities | Underperform → Buy |
| 2025-12-03 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-11-24 | Iniziato | HSBC Securities | Buy |
| 2025-11-24 | Ripresa | Truist | Buy |
| 2025-11-13 | Iniziato | Scotiabank | Sector Perform |
| 2025-08-14 | Iniziato | Rothschild & Co Redburn | Buy |
| 2025-06-30 | Downgrade | Argus | Buy → Hold |
| 2025-05-30 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-05-30 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-05-14 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-04-22 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-02-05 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-01-16 | Downgrade | UBS | Buy → Neutral |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-11-14 | Iniziato | Citigroup | Neutral |
| 2024-09-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-03-12 | Iniziato | Bernstein | Outperform |
| 2024-01-12 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-11-03 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | Reiterato | Oppenheimer | Perform |
| 2023-06-28 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | Aggiornamento | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-03-23 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2023-01-20 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-10-26 | Downgrade | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-09-09 | Aggiornamento | Jefferies | Underperform → Hold |
| 2022-09-09 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Neutral |
| 2022-06-06 | Iniziato | Jefferies | Underperform |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2022-01-05 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-01-03 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | Ripresa | Wells Fargo | Overweight |
| 2021-12-07 | Ripresa | Cowen | Market Perform |
| 2021-12-06 | Iniziato | Goldman | Buy |
| 2021-11-19 | Ripresa | BMO Capital Markets | Outperform |
| 2021-11-05 | Downgrade | The Benchmark Company | Buy → Hold |
| 2021-06-29 | Iniziato | H.C. Wainwright | Buy |
| 2021-01-25 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2021-01-08 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-10-05 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | Downgrade | The Benchmark Company | Buy → Hold |
| 2020-07-09 | Aggiornamento | SunTrust | Hold → Buy |
| 2020-05-26 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | Downgrade | Citigroup | Buy → Neutral |
| 2020-04-17 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2020-04-08 | Iniziato | The Benchmark Company | Hold |
| 2020-03-31 | Iniziato | Wolfe Research | Peer Perform |
| 2020-02-27 | Iniziato | Barclays | Overweight |
| 2020-02-26 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-02-11 | Aggiornamento | Argus | Hold → Buy |
| 2019-12-24 | Iniziato | Raymond James | Mkt Perform |
| 2019-12-16 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-12-13 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | Iniziato | SunTrust | Hold |
| 2019-11-07 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-09-23 | Aggiornamento | Guggenheim | Neutral → Buy |
Mostra tutto
Regeneron Pharmaceuticals Inc Borsa (REGN) Ultime notizie
Is Regeneron (REGN) Offering Value After Recent Share Price Softness? - Yahoo Finance UK
TD Cowen Adjusts Regeneron Pharmaceuticals PT to $820 From $800, Maintains Buy Rating - marketscreener.com
Ruffer LLP Takes $12.11 Million Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Evercore ISI Highlights Dupixent and Eylea HD as Key Growth Drivers For Regeneron Pharmaceuticals, Inc. (REGN) - Insider Monkey
Mirae Asset Global Investments Co. Ltd. Purchases 5,403 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
J. Safra Sarasin Holding AG Purchases 1,741 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
The Escalator: Regeneron, Lundbeck, Amgen and more - Medical Marketing and Media
Alvotech resolves global patent disputes with Regeneron and Bayer over Eylea biosimilar (ALVO:NASDAQ) - Seeking Alpha
Alvotech deal clears way for new Eylea alternative in global markets - Stock Titan
Earnings To Watch: Regeneron (REGN) Reports Q4 Results Tomorrow - The Globe and Mail
NTLA Stock Up More Than 6% as FDA Lifts ATTRv-PN Study Clinical Hold - Finviz
Will Higher Dupixent Profits, Eylea HD Sales Drive REGN's Q4 Earnings? - TradingView
Federated Hermes Inc. Has $132.81 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Cambiar Investors LLC Trims Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Cullen Frost Bankers Inc. - MarketBeat
Eylea HD Approval And STEM Focus Shape Regeneron’s Growth Outlook - simplywall.st
Corvus Pharmaceuticals Stock Rallies 209% in a Month: Here's Why - Finviz
Atopic Dermatitis Market to Reach USD 12.97 Billion by 2034, Growing at 7.75% CAGR - GlobeNewswire Inc.
Regeneron (REGN) Posted Solid Quarterly Results, Eyes 2026 Pipeline Catalysts - Insider Monkey
Analysts Are Bullish on These Healthcare Stocks: Guardant Health (GH), Regeneron (REGN) - The Globe and Mail
Intellia rises as FDA lifts clinical hold on Regeneron-partnered gene editing drug - Seeking Alpha
Lbp Am Sa Grows Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Bernstein Adjusts PT on Regeneron Pharmaceuticals to $916 From $911, Maintains Outperform Rating - marketscreener.com
Compass Wealth Management LLC Buys Shares of 3,634 Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
General American Investors Co. Inc. Increases Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Sovran Advisors LLC Boosts Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Mitsubishi UFJ Trust & Banking Corp - MarketBeat
Regeneron Pharmaceuticals (REGN) Valuation Check After Eylea HD Approval And Ongoing Dupixent Momentum - simplywall.st
Y Intercept Hong Kong Ltd Sells 24,556 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Stoneridge Investment Partners LLC Buys Shares of 2,360 Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Resona Asset Management Co. Ltd. Sells 5,371 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Teacher Retirement System of Texas Sells 2,558 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
What Regeneron Pharmaceuticals (REGN)'s Eylea HD Progress and STEM Investment Push Means For Shareholders - simplywall.st
Oxbow Advisors LLC Takes $2.95 Million Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by Wealth Enhancement Advisory Services LLC - MarketBeat
Regeneron: Q4 Earnings PreviewWhy I'm Expecting A Beat And Strong 2026 (NASDAQ:REGN) - Seeking Alpha
Regeneron (REGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Finviz
Big Pharma shops Chinese biotechs to stock GLP-1 pipelines - Pharma Voice
The Truth About Regeneron Pharmaceuticals: Why Wall Street Can’t Stop Watching REGN - AD HOC NEWS
How Regeneron’s Broader Biologics Pipeline And Capital Return Focus At Regeneron Pharmaceuticals (REGN) Has Changed Its Investment Story - Yahoo Finance
Is Regeneron Pharmaceuticals (REGN) Still Attractive After Recent Share Price Weakness? - simplywall.st
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Regeneron Pharmaceuticals (REGN) Projected to Post Quarterly Earnings on Friday - MarketBeat
Bi Specific Antibodies Therapy Market Is Booming Worldwide | AbbVie • Regeneron Pharmaceuticals • Pfizer - openPR.com
2 Healthcare Stocks Poised for a Comeback in 2026 - Finviz
Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $875.00 at Evercore ISI - MarketBeat
REGN: Evercore ISI Group Raises Price Target to $875, Maintains Outperform Rating | REGN Stock News - GuruFocus
Analysts Crow About Potential Of Corvus Pill To Beat Dupixent - Citeline News & Insights
Universal Beteiligungs und Servicegesellschaft mbH Increases Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Faces Neurology Leadership Shift As Investors Weigh Pipeline Execution - simplywall.st
Ocular Therapeutix Appoints David W. Robinson as Global Chief Commercial Officer - citybiz
Regeneron Pharmaceuticals Inc Azioni (REGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.11%
0.80%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):